OTCMKTS:OPHLF Ono Pharmaceutical (OPHLF) Stock Price, News & Analysis → Elon to Transform U.S. Economy? (From Porter & Company) (Ad) Free OPHLF Stock Alerts $14.91 0.00 (0.00%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$14.91▼$14.9150-Day Range$14.47▼$16.8252-Week Range$14.47▼$20.29VolumeN/AAverage Volume2,171 shsMarket CapitalizationN/AP/E Ratio8.06Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest Get Ono Pharmaceutical alerts: Email Address Ad Weiss RatingsThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-up before it’s too late. It’s urgent because it’s what we consider “The #1 Crypto for the AI World.”Learn more about it by watching THIS NOW. About Ono Pharmaceutical Stock (OTCMKTS:OPHLF)Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has a collaboration with Adimab, LLC to discover novel antibody drugs; a research collaboration with Turbine Ltd. to identify and validate novel oncology targets; Harvard University for validating novel therapeutic targets; and a strategic drug discovery collaboration with Sibylla Biotech in central nervous system disorders. The company was founded in 1717 and is headquartered in Osaka, Japan.Read More OPHLF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OPHLF Stock News HeadlinesApril 30, 2024 | reuters.comJapan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansionApril 29, 2024 | markets.businessinsider.comDeciphera Pharmaceuticals: Hold Rating Amid ONO Pharmaceutical Acquisition PremiumMay 4, 2024 | Awesomely, LLC (Ad)Automatic Income (from home)For over 22 years, Wall Street elites have kept this little-known "income hack" from everyday investors… 6 simple clicks have set up HUGE payouts for "in-the-know" investors… Delivering them passive income 365 days a year. April 29, 2024 | msn.comAbbVie Outlook: Why Humira Biosimilars Won't Undo A Projected $73 Billion In SalesApril 29, 2024 | seekingalpha.comFate Therapeutics: Looking For A Potential Turnaround In 2024April 29, 2024 | marketwatch.comDeciphera Shares Hit 2-Year High After $2.4B Buyout Offer From ONO PharmaApril 29, 2024 | finance.yahoo.comUPDATE 2-Japan's Ono to buy US drugmaker Deciphera for $2.4 blnApril 29, 2024 | finance.yahoo.comDeciphera Catapults 73% On Ono Pharmaceutical's $2.4 Billion TakeoverMay 4, 2024 | Awesomely, LLC (Ad)Automatic Income (from home)For over 22 years, Wall Street elites have kept this little-known "income hack" from everyday investors… 6 simple clicks have set up HUGE payouts for "in-the-know" investors… Delivering them passive income 365 days a year. April 29, 2024 | reuters.comJapan's ONO Pharmaceutical to buy Deciphera for $2.4 billionApril 27, 2024 | forbes.comAI Supercharges Fentanyl Production And Distribution, Study FindsApril 22, 2024 | seekingalpha.comHookipa Pharma: 04/25/24 Update Should Be The First Of Several Positive CatalystsApril 9, 2024 | finance.yahoo.comQ4 2023 Cue Biopharma Inc Earnings CallMarch 20, 2024 | uk.investing.comOno Pharmaceutical Co Ltd (OPHLY)March 14, 2024 | msn.comDon Lemon Says His Talk Show Deal with X Was Canceled After Tense Interview with Elon Musk: 'He's Mad at Me'February 24, 2024 | msn.comOno Pharmaceutical Co., - Depositary Receipt () (OPHLY) Price Target Increased by 19.99% to 7.80February 22, 2024 | finance.yahoo.comOno Enters into a Research Collaboration Agreement with InveniAI to Identify Novel Therapeutic TargetsFebruary 20, 2024 | msn.comLondon exhibition celebrates 'unknown artist' Yoko OnoFebruary 14, 2024 | uk.finance.yahoo.comOno Enters into a Drug Discovery Collaboration and Option Agreement with Shattuck Labs to Generate Bifunctional Fusion ProteinsFebruary 14, 2024 | globenewswire.comNumab Therapeutics and Ono Pharmaceutical Announce an Option and Collaboration Agreement to Develop Multi-specific Antibody NM49 for Treatment of CancerFebruary 5, 2024 | msn.comNVO, LLY or AZN: Which Pharma Stock Is the Best Weight-Loss Investment?February 5, 2024 | investing.comOno Pharmaceutical Ltd (4528)January 16, 2024 | seekingalpha.comODP: A Value Play With CatalystsJanuary 16, 2024 | wsj.comSnack Maker Orion Slumps After Pharma Acquisition PushDecember 21, 2023 | tmcnet.comOno Enters into Research Collaboration with UK Dementia Research InstituteDecember 19, 2023 | markets.businessinsider.comBioMed X Institute and Ono Pharmaceutical Launch New Collaboration in Cancer ResearchDecember 16, 2023 | msn.comOno Pharmaceutical Co. Ltd - ADR (OPHLY) Price Target Increased by 29.83% to 7.51See More Headlines Receive OPHLF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ono Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/04/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:OPHLF CUSIPN/A CIK940821 Webwww.ono.co.jp Phone(166) 263-5670Fax816-6263-2950Employees3,761Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$1.85 Trailing P/E Ratio8.06 Forward P/E Ratio7.93 P/E GrowthN/ANet Income$834.15 million Net Margins25.43% Pretax MarginN/A Return on Equity16.32% Return on Assets14.16% Debt Debt-to-Equity RatioN/A Current Ratio3.52 Quick Ratio3.04 Sales & Book Value Annual Sales$3.31 billion Price / SalesN/A Cash Flow$1.93 per share Price / Cash Flow7.72 Book Value$10.76 per share Price / Book1.39Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta0.66 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Gyo Sagara (Age 66)CEO, President & Representative Director Comp: $885.84kMr. Masaki ItoCorp. Offcr. and Div. Dir. of Corp. Strategy & Planning, Bus. Mgmt., Fin. & Acc. Dept. and Corp. TaxTakehiro YamadaCorporate Officer & Senior Director of Risk & Compliance Mgmt. Dept. and Risk Mgmt. Promotion OfficeMasayuki TanigawaCorporate Officer & Executive Director of Corporate Development & StrategyMr. Toichi Takino Ph.D. (Age 56)Senior Managing Executive Officer, Head of Research Division & Director Mr. Toshihiro Tsujinaka (Age 60)Sr. EO, Executive Director of Sustainability Promotion Corporate Strategy & Planning and Director Hiromu Habashita Ph.D.Corporate Officer, Dep. Executive Dir. of Discovery & Research and Research Center of ImmunologyKiyoaki Idemitsu (Age 60)Managing Executive Officer, GM of Development Division & Director Shinji Takai M.D.Ph.D., Corporate Officer & Head of Medical AffairsSatoshi TakahagiCorporate Officer and Executive Director of Sales, Marketing & Primary Care Business DivisionMore ExecutivesKey CompetitorsAbliva AB (publ)OTCMKTS:NEVPFAcusphereOTCMKTS:ACUSAddex TherapeuticsOTCMKTS:ADDXFAeolus PharmaceuticalsOTCMKTS:AOLSAffymaxOTCMKTS:AFFYView All Competitors OPHLF Stock Analysis - Frequently Asked Questions How have OPHLF shares performed in 2024? Ono Pharmaceutical's stock was trading at $17.6850 at the beginning of 2024. Since then, OPHLF stock has decreased by 15.7% and is now trading at $14.91. View the best growth stocks for 2024 here. How do I buy shares of Ono Pharmaceutical? Shares of OPHLF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:OPHLF) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchAutomatic Income (from home)Awesomely, LLCClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsCould Your Accounts Be Frozen?Allegiance GoldFW: 234x GainWeiss RatingsStock-Picking AI Predicts #1 Stock of 2024Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ono Pharmaceutical Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.